Brigid Bonner

About Brigid Bonner

Brigid Bonner was appointed to Concentra Group Holdings Parent, Inc.’s Board of Directors effective July 1, 2025; she is a non-employee director eligible for director compensation as described in Concentra’s 2025 proxy statement . She is President of Bonner Consulting with 35+ years of senior executive experience across retail, technology, e-commerce, and health care, including roles at CaringBridge, UnitedHealth Group, IBM, Target, The Schwan Food Company, and SimonDelivers.com . She holds a B.S. from Iowa State University and an MBA from Harvard Business School . A Form 3 filed upon appointment reported no beneficial ownership of Concentra securities as of July 1, 2025 .

Past Roles

Organization	Role	Tenure	Committees/Impact
CaringBridge	Senior leadership role	Not disclosed	Digital transformation, consumer experience focus
UnitedHealth Group	Senior leadership role	Not disclosed	Health care strategy; data-driven operations
IBM	Senior leadership role	Not disclosed	Technology and e-commerce initiatives
Target Corporation	Senior leadership role	Not disclosed	Retail and consumer experience strategy
The Schwan Food Company	Senior leadership role	Not disclosed	Business development initiatives
SimonDelivers.com	Senior leadership role	Not disclosed	Start-up/e-commerce operations

External Roles

Organization	Role	Tenure	Committees/Impact
Bonner Consulting	President	Current	Strategy, digital transformation, executive coaching

Board Governance

Appointment and term: Appointed June 26, 2025 (effective July 1, 2025); her term runs until the 2027 Annual Meeting, when she will stand for election along with other nominees .
Independence/related-party: The 8-K states no related-party transactions for Ms. Bonner requiring disclosure under Item 404(a) . Concentra ceased “controlled company” status in Nov 2024 and is phasing to fully independent Compensation and Nominating committees by Nov 2025; Audit must be fully independent within one year of the IPO .
Board composition and leadership: Board expanded to seven directors in June 2025; chairman is Robert A. Ortenzio; Daniel J. Thomas serves as Lead Director with defined responsibilities including presiding over executive sessions and liaising with independent directors .
Committees and current membership (pre-appointment; subject to change): Audit & Compliance (Thomas—chair; Newton; Watkins) ; Human Capital & Compensation (Ortenzio—chair; Thomas; Pegus) ; Nominating, Governance & Sustainability (Ortenzio—chair; Watkins; Pegus) ; Quality of Care & Patient Safety (Pegus—chair; Watkins) . Ms. Bonner’s committee assignments were not disclosed in the appointment 8-K .
Meetings/attendance policy: Board meets at least quarterly; in 2024 there were two board meetings with full attendance by then-current directors; directors are expected to attend annual meetings .

Fixed Compensation

Structure applicable to non-employee directors (Ms. Bonner is eligible per 8-K; actual amounts for her will reflect service timing):

Component	Amount	Notes
Quarterly cash retainer	$12,500	Directors may elect to receive retainer in fully-vested shares
Board meeting fee (in-person)	$3,000 per meeting	$4,000 if Audit & Compliance held independent of a Board meeting
Board meeting fee (telephonic)	$600 per meeting	Applies to telephonic attendance
Audit & Compliance Committee meeting fee (in-person)	$3,000 per meeting	$4,000 if independent of Board meeting
Audit & Compliance Committee meeting fee (telephonic)	$1,500 per meeting	—
Audit & Compliance Committee chair premium	$1,000 in-person; $500 telephonic per meeting	—
Quality of Care & Patient Safety Committee meeting fee (in-person)	$2,000 per meeting	$3,000 if independent of Board meeting
Quality of Care & Patient Safety Committee meeting fee (telephonic)	$1,000 per meeting	—
Other committee meeting fee (in-person)	$1,000 per meeting	$2,000 if independent of Board meeting
Other committee meeting fee (telephonic)	$500 per meeting	—

Stock ownership guidelines for directors: Must own shares equal to five times annual cash compensation (excluding meeting fees), with three years to comply; guidelines recalculated annually .

Performance Compensation

Director equity program (structure at Concentra; Ms. Bonner will be eligible; her individual grant details were not disclosed at appointment):

Item	Details
Annual/onboarding grant (Nov 26, 2024)	12,992 restricted shares to each non-employee director
Vesting	50% (onboarding grant) vests ratably over five years; 50% (annual grant) vests after one year
Grant-date price	$23.09 per share (basis for fair value calculation)
Fair value example (2024)	$299,985 per director stock awards for those serving in 2024
Trading/hedging policy	Directors prohibited from hedging company securities (e.g., collars, swaps, derivatives)

Note: Ms. Bonner’s 8-K specifies eligibility for non-employee director compensation as described in the proxy; her initial Form 3 reported no holdings as of July 1, 2025, and no Form 4 grant was found in filings reviewed .

Other Directorships & Interlocks

Company	Role	Status
Public company boards	Not disclosed in Concentra filings reviewed	None disclosed
Related-party transactions	N/A	None requiring disclosure under Item 404(a) for Ms. Bonner

Expertise & Qualifications

Strategy and digital transformation leader with specialties in strategic planning, business development, consumer experience, and coaching; 35+ years across nonprofit, start-up, Fortune 100 organizations in health care, retail, technology, and e-commerce .
Education: B.S. Iowa State University (journalism/advertising; industrial administration); MBA Harvard Business School .
Appointed alongside Vipin Gopal to strengthen board capabilities in data, AI, technology, and customer experience as Concentra scales post-IPO .

Equity Ownership

Filing	Date	Reported Beneficial Ownership	Notes
Form 3 (Initial Statement)	July 1, 2025	0 shares	Filed with a limited power of attorney appointing Timothy F. Ryan; no securities beneficially owned at appointment
Form 4 (Transactions)	Through Aug 2025	None located	No Form 4 grant/disposition for Ms. Bonner found in reviewed filings [Search result: none]

Director stock ownership guidelines: five times annual cash compensation; three-year compliance window; anti-hedging policy in effect for directors .

Governance Assessment

Independence and conflicts: No related-party transactions disclosed for Ms. Bonner; appointed as a non-employee director with eligibility under standard director compensation policies—favorable for alignment and independence .
Committee assignment transparency: No committee assignment disclosed at appointment; Concentra is in an NYSE phase-in to fully independent Compensation and Nominating committees by Nov 2025 and a fully independent Audit committee within one year of IPO—investors should monitor committee compositions and any leadership roles assigned to Ms. Bonner .
Ownership alignment: Initial Form 3 showed no holdings; stock ownership guidelines require meaningful equity over three years, and anti-hedging enhances alignment—watch for future equity grants and accumulation consistent with guidelines .
Board effectiveness context: Lead Independent Director structure, regular executive sessions, and established committee charters (including Quality of Care oversight) are positives for governance rigor; board expanded to seven directors in June 2025 to strengthen expertise relevant to Concentra’s data and customer-experience initiatives .